Establishment Labs (NASDAQ:ESTA) Sees Unusually-High Trading Volume

Establishment Labs Holdings Inc. (NASDAQ:ESTA) shares saw an uptick in trading volume on Tuesday . 276,145 shares were traded during trading, a decline of 24% from the previous session’s volume of 363,283 shares.The stock last traded at $40.71 and had previously closed at $43.27.

Analysts Set New Price Targets

A number of research firms recently commented on ESTA. JPMorgan Chase & Co. decreased their target price on Establishment Labs from $61.00 to $50.00 and set an “overweight” rating for the company in a report on Wednesday, August 7th. Citigroup lifted their price target on Establishment Labs from $41.00 to $45.00 and gave the company a “neutral” rating in a research report on Thursday, August 22nd. Mizuho lifted their price target on Establishment Labs from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, June 6th. Finally, Stephens reiterated an “overweight” rating and set a $68.00 price target on shares of Establishment Labs in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.60.

Establishment Labs Stock Performance

The company has a current ratio of 4.44, a quick ratio of 2.91 and a debt-to-equity ratio of 4.30. The firm’s fifty day moving average is $43.02 and its 200 day moving average is $47.27. The company has a market cap of $1.04 billion, a PE ratio of -12.74 and a beta of 1.20.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Tuesday, August 6th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). The company had revenue of $44.12 million for the quarter, compared to analysts’ expectations of $43.10 million. Establishment Labs had a negative return on equity of 220.67% and a negative net margin of 54.97%. The firm’s revenue for the quarter was down 9.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.65) EPS. As a group, research analysts predict that Establishment Labs Holdings Inc. will post -2.2 EPS for the current fiscal year.

Insider Activity

In related news, CEO Quiros Juan Jose Chacon sold 3,641 shares of the company’s stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $45.04, for a total transaction of $163,990.64. Following the completion of the sale, the chief executive officer now owns 210,735 shares of the company’s stock, valued at approximately $9,491,504.40. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 11.44% of the company’s stock.

Institutional Trading of Establishment Labs

Large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets raised its stake in Establishment Labs by 32,968.7% during the first quarter. BNP Paribas Financial Markets now owns 97,222 shares of the company’s stock worth $4,949,000 after purchasing an additional 96,928 shares during the period. Stableford Capital II LLC acquired a new stake in shares of Establishment Labs during the 1st quarter worth about $1,568,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Establishment Labs during the 1st quarter worth about $4,185,000. Divisadero Street Capital Management LP purchased a new stake in Establishment Labs in the 2nd quarter valued at about $5,829,000. Finally, Principal Financial Group Inc. acquired a new position in Establishment Labs in the second quarter valued at about $593,000. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.